Cabaletta Bio, Inc. (CABA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-21

Key Insights

Michael Gerard, the General Counsel of Cabaletta Bio, Inc. (CABA), purchased 6,600 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.2696 per share.
This insider buying activity may signal Gerard's confidence in the company's future prospects and could be viewed positively by investors.
The transaction amount is relatively small, suggesting it may not be a significant event, but it still provides insight into the company's leadership's perspective on the stock's valuation.

Want the newest filings?

This analysis covers the filing from 2026-01-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-21

Insider Mark Simon purchased 11,061 shares of Cabaletta Bio, Inc. (CABA) at an average price of $2.2838, increasing his direct ownership to 147,205 shares.
Simon also owns an additional 7,000 shares indirectly through his spouse, indicating a sizable and growing personal stake in the company.
The insider purchase suggests Simon's confidence in Cabaletta Bio's prospects and aligns his interests with those of other shareholders.

Filed: 2026-01-21

The reporting person, Steven Nichtberger, who is the President and CEO of Cabaletta Bio, Inc., has directly acquired 45,000 shares of the company's common stock at a weighted average price of $2.2395 per share.
Nichtberger also holds an indirect beneficial ownership of 363,000 shares through the 2017 Nichtberger Family Trust.
This insider buying activity could be a positive signal for investors, as the CEO is demonstrating confidence in the company's prospects by increasing his personal stake.

Filed: 2026-01-21

Catherine Bollard, a director of Cabaletta Bio, Inc., acquired 4,405 shares of the company's common stock on January 21, 2026 at a price of $2.2661 per share.
This purchase increases Bollard's direct beneficial ownership to 5,405 shares of Cabaletta's common stock.
Insider buying, especially by directors, can be a positive signal about the company's prospects and potential future performance.

Filed: 2026-01-21

Steve Gavel, the Chief Commercial Officer of Cabaletta Bio, Inc. (CABA), has directly purchased 22,170 shares of the company's common stock on January 21, 2026 at a weighted average price of $2.265 per share.
This insider buying activity suggests that Gavel has confidence in the company's future prospects and is willing to invest his own capital in the stock.
The purchase of a sizable number of shares by a key executive could signal positive sentiment within the company and may be viewed favorably by investors.

Filed: 2026-01-21

Insider Shawn Tomasello acquired 22,725 shares of Cabaletta Bio, Inc. (CABA) at $2.2144 per share, indicating his confidence in the company's prospects.
The transaction represents a direct ownership increase for Tomasello, further aligning his interests with those of other shareholders.
Insider buying of this magnitude can be viewed as a positive signal, as insiders typically have superior information about the company's future performance.

Filed: 2026-01-21

Insider Gwendolyn Binder, the President of Science and Technology, purchased 11,312 shares of Cabaletta Bio, Inc. (CABA) at $2.1891 per share, indicating confidence in the company's prospects.
This insider purchase represents a direct ownership increase of 56.4% for Binder, signaling a positive view on the company's future performance.
Insider buying is often seen as a positive signal, as it suggests the reporting person believes the stock is undervalued and has potential for future growth.

Filed: 2026-01-21

The reporting person, David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., has acquired 8,800 shares of the company's common stock at a price of $2.26 per share.
This purchase suggests that the insider has a positive outlook on the company's future prospects and is willing to increase their ownership stake.
The timing of the transaction, which occurred on January 21, 2026, may indicate the insider's confidence in the company's near-term performance or upcoming events.

Other reports for Cabaletta Bio, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.